Highlights Argos Therapeutics, Inc.

Equities

ARGSQ

US0402212023

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

2019	Argos Therapeutics, Inc. Went Out of Business	CI
2019	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	12/02/19	CI
Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	21/01/19	CI
CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	21/01/19	CI
CELLSCRIPT, LLC and Cell Therapies, LLC entered into an asset purchase agreement to acquire Substantially All of the Non-Cash Assets of Argos Therapeutics, Inc. for approximately $1.7 million.	29/11/18	CI
Argos Therapeutics, Inc. Reports Results of Interim Analysis of the Adapt Trial and Announces Review of Strategic Alternatives	19/04/18	CI
Argos Therapeutics, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	02/04/18	CI
Argos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	09/11/17	CI
Argos Therapeutics Inc. Reports on Interim Analysis of Phase 3 ADAPT Trial	12/09/17	CI
Argos Therapeutics Inc. Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir	06/09/17	CI
Argos Therapeutics, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	09/08/17	CI
Argos Therapeutics Provides Update on ADAPT Trial	10/05/17	CI
Argos Therapeutics to Continue Adapt Trial Despite IDMC Recommendation to Discontinue Study	18/04/17	CI
Argos Therapeutics Inc. Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial	18/04/17	CI
Independent Data Monitoring Committee Recommends Discontinuation of the Argos Therapeutics, Inc.'s ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility	22/02/17	CI
Argos Therapeutics Seeks Acquisitions	09/01/17	CI
Argos Therapeutics Plans to Build New Production Facility to Make Renal Cell Cancer Treatment	08/12/16	CI
Argos Therapeutics, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	14/11/16	CI
Argos Therapeutics, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	10/08/16	CI
Argos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV	14/07/16	CI
Argos Therapeutics, Inc. Enters into Strategic Research Agreement with Adaptive Biotechnologies Corporation	15/06/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Argos Therapeutics, Inc.

Equities

ARGSQ

US0402212023

Highlights

Filters